Intuitive Surgical reports Q1 2026 results on April 30, and the dominant story is a Street that remains broadly constructive even after trimming its ambitions.
Analyst activity in the past two weeks has run almost entirely in one direction on price targets — down — but that hasn't dented buy-side conviction. Barclays cut its target to $651 from $712 while holding Overweight. Goldman Sachs lowered to $609 from $714 yet kept its Buy rating. Leerink Partners and Piper Sandler both pulled targets lower, each maintaining Outperform and Overweight calls respectively. Only Baird bucked the tide, raising its target to $610 from $575 while reiterating Outperform. The consensus mean now sits at $577 — a 24% premium to the current price of $466.64 — and analyst return potential registers at 22.5%. That's not a cautious Street; it's one taking targets down to reflect macro uncertainty while staying long the thesis.
Bulls anchor on the robotic surgery moat. With more than 10,000 da Vinci systems installed globally and an operating margin running near 39%, the platform economics are hard to replicate. Procedure volume growth in the US and internationally remains the primary growth engine, with the da Vinci 5 rollout adding a product cycle overlay. Bears point to valuation friction: at roughly 43x trailing earnings and 30x EV/EBITDA, the stock commands a premium that leaves little room for stumbles. EV/EBITDA has compressed about 2.5 points over the past 30 days — a de-rating move that reflects both the stock's 17% YTD decline and the broader med-tech multiple reset. The bear case adds that Ion and SP systems are converging in utilization, narrowing the runway for incremental penetration gains. Factor scores cut both ways: EPS momentum ranks in the 82nd percentile over 30 days, and the company's track record of beating estimates ranks in the 74th percentile — but the 12-month forward EPS growth outlook places only in the 30th percentile, a signal that consensus is not modelling an acceleration.
Positioning into the print looks relaxed rather than charged. Short interest is modest at 1.9% of free float and fell 6.2% over the past week — bears have been covering, not piling in. Cost to borrow is negligible at 0.36%, and while borrow availability has tightened in recent sessions, the ORTEX short score of 32.9 is well below any threshold that would signal squeeze dynamics. Options tell a slightly more interesting story: the put/call ratio has dropped to 0.885, more than one standard deviation below its 20-day average of 0.938. That's near its 52-week low reading. Far from hedging defensively, options traders have been rotating into calls — a positioning skew that leans bullish into the release. Peers ALGN and SIBN fell 9.2% and 10.6% respectively over the past week, while ISRG gained 3.4% — a notable divergence that implies the market is already assigning ISRG a relative-quality premium heading into earnings season.
The Q1 print will test whether da Vinci 5 system placements and procedure volumes are tracking at a pace that supports the premium multiple — and whether ISRG can hold its ground as peers reprice downward.
See the live data behind this article on ORTEX.
Open ISRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
